

Adam S Kibel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6915614/publications.pdf>

Version: 2024-02-01

364
papers

18,455
citations

15495

65
h-index

18115

120
g-index

375
all docs

375
docs citations

375
times ranked

20427
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279.	0.6	2
2	The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients. <i>IEEE Transactions on Biomedical Engineering</i> , 2022, 69, 412-421.	2.5	9
3	Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. <i>Journal of the National Cancer Institute</i> , 2022, 114, 310-313.	3.0	2
4	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 771-774.	3.0	39
5	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 229-237.	2.0	9
6	Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 320-326.	2.0	4
7	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2022, 81, 458-462.	0.9	22
8	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
9	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	0.9	12
10	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS285-TPS285.	0.8	3
11	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022, 40, 281-281.	0.8	1
12	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	3
13	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab097.	1.4	5
14	Hormone Treatment of Prostate Cancer.. <i>Urologic Clinics of North America</i> , 2022, 49, 309-321.	0.8	1
15	<i>RB1</i> loss overrides PARP inhibitor sensitivity driven by <i>RNASEH2B</i> loss in prostate cancer. <i>Science Advances</i> , 2022, 8, eabl9794.	4.7	14
16	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 3106-3109.	0.8	16
17	Preoperative anemia is associated with increased radical cystectomy complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e7-382.e13.	0.8	1
18	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1644-1650.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. <i>Molecular Cancer Research</i> , 2021, 19, 475-484.	1.5	22
20	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 719-726.	3.0	45
21	Access denied: The relationship between patient insurance status and access to high-volume hospitals. <i>Cancer</i> , 2021, 127, 577-585.	2.0	26
22	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	0.8	4
23	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394.	2.0	10
24	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 99-105.	2.3	24
25	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2021, 4, 66-72.	2.6	20
26	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	1.6	31
27	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
28	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
29	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
30	Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. <i>European Urology</i> , 2021, 79, 405-412.	0.9	22
31	EZH2 inhibition activates a dsRNA-STING interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	5.7	118
32	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , 2021, 11, 9264.	1.6	5
33	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1274-1274.	0.2	0
34	One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. <i>BMC Urology</i> , 2021, 21, 81.	0.6	1
35	A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2171-2186.	1.8	14
36	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. <i>Journal of Urology</i> , 2021, 205, 1263-1274.	0.2	10

#	ARTICLE	IF	CITATIONS
37	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e654-e665.	1.4	11
38	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 733-741.	0.6	4
39	Domain adaptation for segmentation of critical structures for prostate cancer therapy. <i>Scientific Reports</i> , 2021, 11, 11480.	1.6	8
40	Abstract 822: Can the genetic risk of prostate cancer be attenuated by a healthy lifestyle. , 2021, , .		2
41	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 436.e1-436.e10.	0.8	4
42	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. <i>Minerva Urology and Nephrology</i> , 2021, 73, 404-406.	1.3	3
43	Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 550-558.	0.4	0
44	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2021, 80, 295-303.	0.9	15
45	Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 678-685.	0.8	3
46	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. <i>Investigative and Clinical Urology</i> , 2021, 62, 56.	1.0	4
47	Epidemiology and Prevention of Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 877-892.	2.6	190
48	Perioperative Acid Suppression in Bladder Cancer Patients Undergoing Radical Cystectomy: A Population-Based Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 233, S309.	0.2	0
49	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 74-80.	1.6	8
50	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 81-87.	2.0	39
51	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 135, 44-49.	0.5	5
52	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. <i>Cancer</i> , 2020, 126, 496-505.	2.0	19
53	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. <i>Journal of Surgical Oncology</i> , 2020, 121, 578-583.	0.8	6
54	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 74.e13-74.e20.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1929-1936.	0.7	3
56	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	1.1	19
57	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , 2020, 38, 2227-2236.	1.2	12
58	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 410-418.	2.0	17
59	Risk factors and reasons for reoperation after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 269-277.	0.8	13
60	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. <i>BMC Surgery</i> , 2020, 20, 235.	0.6	2
61	EDITORIAL COMMENT. <i>Urology</i> , 2020, 139, 42-43.	0.5	0
62	AUTHOR REPLY. <i>Urology</i> , 2020, 140, 121.	0.5	0
63	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16
64	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020, 3, e201839.	2.8	37
65	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	0.9	32
66	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	1.4	14
67	Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 290-296.	0.6	1
68	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
69	miR-218 Expressed in Endothelial Progenitor Cells Contributes to the Development and Repair of the Kidney Microvasculature. <i>American Journal of Pathology</i> , 2020, 190, 642-659.	1.9	13
70	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 140.	3.8	36
71	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. <i>JAMA Network Open</i> , 2020, 3, e1919185.	2.8	18
72	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 140, 115-121.	0.5	6

#	ARTICLE	IF	CITATIONS
73	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659.	0.9	7
74	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. <i>JAMA Network Open</i> , 2020, 3, e2030072.	2.8	87
75	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. <i>Journal of Urology</i> , 2020, 203, 522-529.	0.2	75
76	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5503-5503.	0.8	7
77	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS383-TPS383.	0.8	8
78	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. <i>Journal of Clinical Oncology</i> , 2020, 38, 39-39.	0.8	0
79	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 280-280.	0.8	0
80	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20224.	1.8	14
81	Case of the Month from Brigham and Women's Hospital, Boston, MA, USA: a 70-year-old man with lung cysts and bilateral renal masses. <i>BJU International</i> , 2020, 126, 428-432.	1.3	0
82	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1060-e1068.	0.9	11
83	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. <i>Journal of Oncology Practice</i> , 2019, 15, e547-e559.	2.5	8
84	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 14573-14582.	3.3	69
85	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
86	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
87	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e488-e493.	0.9	11
88	Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. <i>JAMA Network Open</i> , 2019, 2, e187633.	2.8	60
89	The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. <i>Cancer Causes and Control</i> , 2019, 30, 871-876.	0.8	21
90	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e194634.	2.8	23

#	ARTICLE	IF	CITATIONS
91	The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?. BJU International, 2019, 123, 748-749.	1.3	0
92	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	0.8	5
93	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8
94	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
95	Adverse Histopathologic Characteristics in Small Clear Cell Renal Cell Carcinomas Have Negative Impact on Prognosis. American Journal of Surgical Pathology, 2019, 43, 1413-1420.	2.1	9
96	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	2.6	6
97	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	0.9	43
98	Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2019, 17, 263-276.	1.5	27
99	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53
100	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
101	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal of Urology, 2019, 37, 2059-2065.	1.2	40
102	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
103	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56
104	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
105	Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015. European Urology, 2019, 75, 696-697.	0.9	0
106	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
107	Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer, 2019, 125, 798-806.	2.0	24
108	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU International, 2019, 124, 40-46.	1.3	17

#	ARTICLE	IF	CITATIONS
109	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.2	31
110	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. <i>Urology Practice</i> , 2019, 6, 159-164.	0.2	3
111	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , 2019, 201, 728-734.	0.2	4
112	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1049-1058.	2.3	21
113	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5100-TPS5100.	0.8	6
114	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 573-581.	0.2	31
115	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 143-154.	0.8	17
116	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17.	0.8	21
117	Reassessing the value of high-volume cancer care in the era of precision medicine. <i>Cancer</i> , 2018, 124, 1319-1321.	2.0	20
118	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1417-1425.	0.2	70
119	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 364-372.	2.0	48
120	The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. <i>International Journal of Cancer</i> , 2018, 142, 2011-2018.	2.3	3
121	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e1-88.e9.	0.8	52
122	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 712-712.	0.2	0
123	Factors Influencing Prostate Specific Antigen Testing in the United States. <i>Urology Practice</i> , 2018, 5, 438-443.	0.2	1
124	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.4	153
125	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436.	1.3	30
126	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 307-317.e1.	0.6	26

#	ARTICLE	IF	CITATIONS
127	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139.	0.9	17
128	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 225.	3.4	58
129	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018, 124, 55-64.	2.0	40
130	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 78.e13-78.e19.	0.8	16
131	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018, 73, 445-451.	0.9	43
132	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	0.9	62
133	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	5.8	43
134	The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e11-500.e19.	0.8	10
135	Use of Preventive Health Services Among Cancer Survivors in the U.S.. <i>American Journal of Preventive Medicine</i> , 2018, 55, 830-838.	1.6	11
136	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E1185-E1193.	1.8	24
137	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. <i>Journal of the Endocrine Society</i> , 2018, 2, 485-496.	0.1	33
138	Contemporary trends in the utilisation of radical prostatectomy. <i>BJU International</i> , 2018, 122, 726-728.	1.3	7
139	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , 2018, 1, 143-148.	2.6	19
140	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 2525-2536.	6.3	537
141	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. <i>Canadian Urological Association Journal</i> , 2018, 13, 32-37.	0.3	2
142	Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. <i>Prostate</i> , 2018, 78, 927-937.	1.2	39
143	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4662-4671.	3.2	27
144	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774.	1.2	12

#	ARTICLE	IF	CITATIONS
145	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018, 34, 4141-4150.	1.8	3
146	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
147	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88
148	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. <i>Bioinformatics</i> , 2017, 33, 822-833.	1.8	11
149	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. <i>Urology Practice</i> , 2017, 4, 388-394.	0.2	2
150	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 210-217.	0.2	1
151	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 852-860.	0.8	104
152	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. <i>Journal of Urology</i> , 2017, 198, 297-304.	0.2	35
153	Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. <i>Abdominal Radiology</i> , 2017, 42, 2154-2159.	1.0	5
154	Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. <i>Prostate</i> , 2017, 77, 1000-1011.	1.2	29
155	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROIMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	2.0	66
156	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487.	0.9	110
157	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	3.2	80
158	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2451-2459.	3.2	58
159	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	3.4	120
160	Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure. <i>Journal of Urology</i> , 2017, 198, 493-495.	0.2	0
161	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , 2017, 198, 1061-1068.	0.2	31
162	The association between germline <i>BRCA2</i> variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , 2017, 123, 3532-3539.	2.0	217

#	ARTICLE	IF	CITATIONS
163	Resident Involvement in Radical Inguinal Orchiectomy for Testicular Cancer Does Not Adversely Impact Perioperative Outcomes - A Retrospective Study. <i>Urologia Internationalis</i> , 2017, 98, 472-477.	0.6	4
164	Assessing robot-assisted laparoscopic prostatectomy. <i>Lancet, The</i> , 2017, 389, 799.	6.3	5
165	The association of hypoalbuminemia with early perioperative outcomes – A comprehensive assessment across 16 major procedures. <i>American Journal of Surgery</i> , 2017, 214, 871-883.	0.9	42
166	Exploring exposure to Agent Orange and increased mortality due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 627-632.	0.8	6
167	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. <i>Journal of Urology</i> , 2017, 198, 1295-1300.	0.2	10
168	Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. <i>Journal of Urology</i> , 2017, 198, 1397-1403.	0.2	3
169	Approach to the Patient with High-Risk Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 635-645.	0.8	6
170	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , 2017, 140, 322-328.	2.3	17
171	Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. <i>Kidney International</i> , 2017, 91, 129-143.	2.6	38
172	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017, 140, 75-85.	2.3	28
173	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	57
174	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 143-143.	0.8	1
175	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 305-305.	0.8	63
176	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332.	0.8	1
177	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. <i>PLoS ONE</i> , 2017, 12, e0184166.	1.1	28
178	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review.. <i>Journal of Clinical Oncology</i> , 2017, 35, 150-150.	0.8	1
179	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-24.	0.8	0
180	Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 162-162.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.. Journal of Clinical Oncology, 2017, 35, 163-163.	0.8	0
182	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5046-5046.	0.8	0
183	Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Canadian Journal of Urology, 2017, 24, 8759-8764.	0.0	11
184	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
185	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate, 2016, 76, 479-490.	1.2	12
186	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
187	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	2.3	93
188	<i>PALB2</i>,<i>CHEK2</i>and<i>ATM</i>rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
189	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	1.6	7
190	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	0.5	10
191	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	0.8	43
192	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	0.8	33
193	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prevention Research, 2016, 9, 933-941.	0.7	18
194	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. British Journal of Cancer, 2016, 115, 624-631.	2.9	23
195	Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533.	2.3	26
196	Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136.	1.3	68
197	Rare Variation in <i>TET2</i> Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1456-1463.	1.1	22
198	Risk of Small Bowel Obstruction After Robot-Assisted <i>vs</i> Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	1.1	4

#	ARTICLE	IF	CITATIONS
199	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
200	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	5.8	50
201	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	2.3	42
202	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 1090-1095.	0.2	42
203	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	0.8	70
204	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711.	0.8	74
205	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. <i>Journal of Urology</i> , 2016, 195, 399-405.	0.2	8
206	Causes of hospital readmissions after urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 236.e1-236.e11.	0.8	36
207	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. <i>British Journal of Cancer</i> , 2016, 114, 945-952.	2.9	17
208	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 85.	3.4	86
209	The impact of histological variants on bladder cancer survival: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 458-458.	0.8	1
210	Sipuleucel-T (sip-T)-induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. <i>Journal of Clinical Oncology</i> , 2016, 34, 165-165.	0.8	1
211	Sipuleucel-T (sip-T)-induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e23116-e23116.	0.8	0
212	Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5053-5053.	0.8	0
213	Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16558-e16558.	0.8	0
214	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1131-1138.	2.3	37
215	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. <i>Annals of Surgery</i> , 2015, 262, 955-964.	2.1	101
216	An evaluation of the "weekend effect"™ in patients admitted with metastatic prostate cancer. <i>BJU International</i> , 2015, 116, 911-919.	1.3	8

#	ARTICLE	IF	CITATIONS
217	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	1.2	54
218	Treatment Decision Making in Patients with Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 151-158.	0.2	25
219	Impact of smoking on perioperative outcomes after major surgery. <i>American Journal of Surgery</i> , 2015, 210, 221-229.e6.	0.9	69
220	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. <i>European Urology</i> , 2015, 68, 32-39.	0.9	43
221	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. <i>Urology</i> , 2015, 85, 764-770.	0.5	18
222	Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancer-specific Mortality by Nomogram-predicted Risks of Biochemical Recurrence. <i>European Urology</i> , 2015, 67, 204-209.	0.9	38
223	Transperineal In-Bore 3-T MR Imaging-guided Prostate Biopsy: A Prospective Clinical Observational Study. <i>Radiology</i> , 2015, 274, 170-180.	3.6	75
224	The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. <i>BJU International</i> , 2015, 115, 198-205.	1.3	73
225	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	0.5	21
226	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	0.9	190
227	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , 2015, 5, 368-379.	7.7	56
228	Generalizability of established prostate cancer risk variants in men of African ancestry. <i>International Journal of Cancer</i> , 2015, 136, 1210-1217.	2.3	62
229	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 1160-1167.	0.9	192
230	Re: Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. <i>European Urology</i> , 2015, 67, 174.	0.9	2
231	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. <i>Journal of Endourology</i> , 2015, 29, 1052-1058.	1.1	23
232	Preventable mortality after common urological surgery: failing to rescue?. <i>BJU International</i> , 2015, 115, 666-674.	1.3	11
233	The impact of robotic surgery on the surgical management of prostate cancer in the USA. <i>BJU International</i> , 2015, 115, 929-936.	1.3	78
234	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. <i>Urology</i> , 2015, 85, 937-941.	0.5	21

#	ARTICLE	IF	CITATIONS
235	New Trends in the Surgical Management of Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 253-269.	0.9	9
236	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). <i>American Journal of Cardiology</i> , 2015, 115, 1080-1084.	0.7	16
237	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. <i>World Journal of Urology</i> , 2015, 33, 2107-2113.	1.2	16
238	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. <i>World Journal of Surgery</i> , 2015, 39, 2376-2385.	0.8	69
239	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	0.8	77
240	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	1.4	67
241	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. <i>Journal of Surgical Education</i> , 2015, 72, 1018-1025.	1.2	36
242	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 503.e7-503.e15.	0.8	9
243	Genome-Wide Association Study of Prostate Cancer-Specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	1.1	27
244	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e9-504.e17.	0.8	21
245	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. <i>Cancer Causes and Control</i> , 2015, 26, 1751-1759.	0.8	7
246	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 17.e9-17.e18.	0.8	24
247	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , 2015, 85, 101-106.	0.5	241
248	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <sc>USA</sc>: a contemporary population-based analysis. <i>BJU International</i> , 2015, 115, 713-721.	1.3	79
249	Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5030-5030.	0.8	3
250	Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 171-171.	0.8	3
251	Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. <i>Canadian Journal of Urology</i> , 2015, 22, 8048-55.	0.0	9
252	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. <i>Canadian Urological Association Journal</i> , 2014, 8, 681.	0.3	51

#	ARTICLE	IF	CITATIONS
253	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004129.	1.5	34
254	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1259-1266.	0.8	50
255	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. <i>JAMA Surgery</i> , 2014, 149, 1039.	2.2	109
256	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. <i>JAMA Internal Medicine</i> , 2014, 174, 1839.	2.6	33
257	The impact of resident involvement in minimally-invasive urologic oncology procedures. <i>Canadian Urological Association Journal</i> , 2014, 8, 334.	0.3	46
258	Clinical Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1048-1056.	0.4	71
259	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. <i>European Urology</i> , 2014, 66, 569-576.	0.9	205
260	Reply to Michael Froehner's Letter to the Editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. <i>Eur Urol</i> 2013;64:372-8. <i>European Urology</i> , 2014, 65, e42.	0.9	0
261	Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2014, 65, 340-347.	0.9	242
262	Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. <i>European Urology</i> , 2014, 65, 1069-1075.	0.9	75
263	Cytoreductive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma (<sc>RCC</sc>). <i>BJU International</i> , 2014, 113, E67-74.	1.3	62
264	Efficacy of robot-assisted radical cystectomy (<sc>RARC</sc>) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (<sc>IRCC</sc>). <i>BJU International</i> , 2014, 114, 98-103.	1.3	14
265	Mental health outcomes in elderly men with prostate cancer: Equal contribution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1333-1340.	0.8	59
266	Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. <i>Journal of Endourology</i> , 2014, 28, 831-840.	1.1	64
267	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. <i>Journal of Clinical Oncology</i> , 2014, 32, 1419-1426.	0.8	169
268	Chronic kidney disease and perioperative outcomes in urological oncological surgery. <i>International Journal of Urology</i> , 2014, 21, 1245-1252.	0.5	14
269	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	9.4	408
270	Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. <i>Cancer</i> , 2014, 120, 1608-1610.	2.0	4

#	ARTICLE	IF	CITATIONS
271	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. <i>Journal of Clinical Oncology</i> , 2014, 32, 1889-1894.	0.8	229
272	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. <i>Journal of Urology</i> , 2014, 191, 1678-1684.	0.2	19
273	A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. <i>Reviews in Urology</i> , 2014, 16, 172-80.	0.9	20
274	Readmissions after major urologic cancer surgery. <i>Canadian Journal of Urology</i> , 2014, 21, 7537-46.	0.0	24
275	Who should be included in a clinical trial of screening for bladder cancer?. <i>Cancer</i> , 2013, 119, 143-149.	2.0	35
276	Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. <i>Eur Urol</i> 2013;64:58-9. <i>European Urology</i> , 2013, 64, 60-61.	0.9	0
277	The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) Initiative: Rationale and Design. <i>Cancer Causes and Control</i> , 2013, 24, 695-704.	0.8	48
278	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. <i>European Urology</i> , 2013, 63, 214-230.	0.9	214
279	Editorial Comment. <i>Journal of Urology</i> , 2013, 189, 853-853.	0.2	0
280	Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2013, 64, 52-57.	0.9	189
281	Response to Letter to the Editor. <i>Journal of Urology</i> , 2013, , .	0.2	0
282	Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 894-898.	0.8	46
283	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. <i>European Urology</i> , 2013, 64, 372-378.	0.9	71
284	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	9.4	492
285	Constitutive β -Catenin Activation Induces Male-Specific Tumorigenesis in the Bladder Urothelium. <i>Cancer Research</i> , 2013, 73, 5914-5925.	0.4	56
286	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013, 22, 2520-2528.	1.4	100
287	¹¹ C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. <i>Journal of Nuclear Medicine</i> , 2013, 54, 699-706.	2.8	81
288	Predicting Risk of Bladder Cancer Using Clinical and Demographic Information from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Participants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2241-2249.	1.1	7

#	ARTICLE	IF	CITATIONS
289	Impact of surgeon and volume on extended lymphadenectomy at the time of robotâ€ assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (<scp>IRCC</scp>). BJU International, 2013, 111, 1075-1080.	1.3	49
290	Adjuvant leuprolide with or without docetaxel in patients with highâ€ risk prostate cancer after radical prostatectomy (TAXâ€3501). Cancer, 2013, 119, 3610-3618.	2.0	51
291	A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.. Journal of Clinical Oncology, 2013, 31, 5016-5016.	0.8	5
292	Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).. Journal of Clinical Oncology, 2013, 31, 34-34.	0.8	8
293	Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-3501 trial.. Journal of Clinical Oncology, 2013, 31, 5023-5023.	0.8	0
294	Preface. Urologic Clinics of North America, 2012, 39, xv.	0.8	0
295	Comparative Analysis of Outcomes and Costs Following Open Radical Cystectomy Versus Robot-Assisted Laparoscopic Radical Cystectomy: Results From the US Nationwide Inpatient Sample. European Urology, 2012, 61, 1239-1244.	0.9	149
296	Ureteral injury in laparoscopic gynecologic surgery. Reviews in Obstetrics and Gynecology, 2012, 5, 106-111.	0.7	37
297	Ability of Linear Length of Positive Margin in Radical Prostatectomy Specimens to Predict Biochemical Recurrence. Urology, 2011, 77, 1409-1414.	0.5	46
298	Positive Margin During Partial Nephrectomy: Does Cancer Remain in the Renal Remnant?. Urology, 2011, 77, 1400-1403.	0.5	66
299	Indications and Practice With Androgen Deprivation Therapy. Urology, 2011, 78, S478-S481.	0.5	5
300	Targeting the Androgen Receptorâ€ Theory and Practice. Urology, 2011, 78, S482-S484.	0.5	6
301	The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 738-744.	0.8	34
302	Lymphadenectomy at the time of robotâ€ assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU International, 2011, 107, 642-646.	1.3	93
303	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics, 2011, 43, 570-573.	9.4	198
304	Re: Active Surveillance Compared with Initial Treatment for Men with Low-Risk Prostate Cancer: A Decision Analysis. European Urology, 2011, 59, 883-884.	0.9	1
305	Editorial for â€ prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostateâ€ specific antigen at or before age 50â€. Cancer, 2011, 117, 1110-1112.	2.0	0
306	Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Cancer: A Washington University Update. Journal of Endourology, 2011, 25, 1753-1757.	1.1	18

#	ARTICLE	IF	CITATIONS
307	Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence. <i>Clinical Cancer Research</i> , 2011, 17, 1075-1081.	3.2	44
308	Prediction of Erectile Function Following Treatment for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1205.	3.8	253
309	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 23-32.	1.1	88
310	The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence. <i>American Journal of Surgical Pathology</i> , 2010, 34, 994-1001.	2.1	73
311	High-risk localized prostate cancer: role of radical prostatectomy. <i>Current Opinion in Urology</i> , 2010, 20, 204-210.	0.9	15
312	The Learning Curve of Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2010, 58, 197-202.	0.9	213
313	Reply from Authors re: Urs E. Studer, Laurence Collette. Robot-Assisted Cystectomy: Does It Meet Expectations? <i>Eur Urol</i> 2010;58:203-4. <i>European Urology</i> , 2010, 58, 204-206.	0.9	0
314	Rebuttal to Dr. Wallner. <i>Brachytherapy</i> , 2010, 9, 200-201.	0.2	1
315	Counterpoint: Prostate carcinoma treatment for the young patient—The case for radical prostatectomy. <i>Brachytherapy</i> , 2010, 9, 195-198.	0.2	1
316	Association of <i>CASP8 D302H</i> polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , 2010, 70, 646-653.	1.2	18
317	Does Previous Robot-assisted Radical Prostatectomy Experience Affect Outcomes at Robot-assisted Radical Cystectomy? Results from the International Robotic Cystectomy Consortium. <i>Urology</i> , 2010, 76, 1111-1116.	0.5	50
318	Prospective Study of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4314-4320.	0.8	219
319	Prostate Cancer Risk Associated Loci in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2145-2149.	1.1	57
320	Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. <i>Carcinogenesis</i> , 2009, 30, 769-776.	1.3	142
321	Intravesical Bacille Calmette-Guérin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy. <i>Journal of the American College of Surgeons</i> , 2009, 209, 248-253.	0.2	17
322	Re: Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. <i>European Urology</i> , 2009, 56, 1089-1090.	0.9	1
323	The role of systemic cytotoxic therapy for prostate cancer. <i>BJU International</i> , 2009, 103, 8-17.	1.3	28
324	Commentary on Transcriptome sequencing to detect gene fusions in cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 461-462.	0.8	0

#	ARTICLE	IF	CITATIONS
325	Commentary on Cumulative association of five genetic variants with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 462-463.	0.8	0
326	Commentary on Germline SDHB mutations and familial renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 463-464.	0.8	0
327	Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. <i>Prostate</i> , 2008, 68, 1179-1186.	1.2	23
328	Evaluation of a novel precision templateâ€guided biopsy system for detecting prostate cancer. <i>BJU International</i> , 2008, 102, 546-550.	1.3	49
329	Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. <i>Nature Genetics</i> , 2008, 40, 1032-1034.	9.4	83
330	Prognostic Impact of Comorbidity in Patients with Bladder Cancer. <i>European Urology</i> , 2008, 53, 581-589.	0.9	48
331	Intravesical BCG therapy for non-muscle-invasive bladder cancer: Effect of concurrent statin therapy. <i>Journal of the American College of Surgeons</i> , 2008, 207, S110-S111.	0.2	0
332	Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma. <i>Urology</i> , 2008, 72, 359-363.	0.5	43
333	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. <i>New England Journal of Medicine</i> , 2008, 358, 1250-1261.	13.9	2,030
334	SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. <i>Human Molecular Genetics</i> , 2007, 17, 1031-1042.	1.4	170
335	Prostate-Specific Antigen Density Predicts Adverse Pathology and Increased Risk of Biochemical Failure. <i>Urology</i> , 2007, 69, 1121-1127.	0.5	54
336	The use and abuse of data: Nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 333-337.	0.8	9
337	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 447-448.	0.8	1
338	TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 448-449.	0.8	3
339	Integrative molecular concept modeling of prostate cancer progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 449-450.	0.8	0
340	An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 450.	0.8	0
341	Trends in nephron-sparing surgery for renal neoplasia. <i>Urology</i> , 2006, 68, 732-736.	0.5	12
342	Single nucleotide polymorphisms: Early diagnosis and risk assessment in genitourinary malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 224-230.	0.8	0

#	ARTICLE	IF	CITATIONS
343	Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. <i>Prostate</i> , 2006, 66, 49-56.	1.2	44
344	Parenchymal imaging adds diagnostic utility in evaluating haematuria. <i>BJU International</i> , 2005, 95, 64-67.	1.3	3
345	An interdisciplinary approach to treating prostate cancer. <i>Urology</i> , 2005, 65, 13-18.	0.5	11
346	Laparoscopic renal surgery and the risk of rhabdomyolysis: Diagnosis and treatment. <i>Urology</i> , 2005, 66, 29-35.	0.5	88
347	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , 2004, 109, 668-672.	2.3	21
348	Xq27-28 deletions in prostate carcinoma. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 381-388.	1.5	14
349	Hemostatic laparoscopic partial nephrectomy assisted by a water-cooled, high-density, monopolar device without renal vascular control. <i>Urology</i> , 2003, 61, 906-909.	0.5	54
350	Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care. <i>Urology</i> , 2003, 62, 821-826.	0.5	62
351	Modified renal morcellation for renal cell carcinoma: laboratory experience and early clinical application. <i>Urology</i> , 2003, 62, 632-634.	0.5	30
352	¹¹ C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. <i>Journal of Nuclear Medicine</i> , 2003, 44, 549-55.	2.8	209
353	CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. <i>Cancer Research</i> , 2003, 63, 2033-6.	0.4	76
354	Laparoscopic Partial Nephrectomy with a Novel Electrosurgical Snare in a Porcine Model. <i>Journal of Endourology</i> , 2002, 16, 673-679.	1.1	15
355	Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. <i>Cancer</i> , 2002, 95, 1239-1246.	2.0	27
356	Mutational analysis of ETV6 in prostate carcinoma. <i>Prostate</i> , 2002, 52, 305-310.	1.2	19
357	Methylation and mutational analysis of p27kip1 in prostate carcinoma. <i>Prostate</i> , 2001, 48, 248-253.	1.2	35
358	G1/S cell cycle proteins as markers of aggressive prostate carcinoma. <i>Urology</i> , 2000, 55, 316-322.	0.5	15
359	Prostatic Diseases. <i>Journal of Urology</i> , 2000, 163, 2054-2054.	0.2	0
360	Familial Calcium Stone Disease: <i>Taq</i> Polymorphism and the Vitamin D Receptor. <i>Journal of Endourology</i> , 1999, 13, 313-316.	1.1	59

#	ARTICLE	IF	CITATIONS
361	PROGNOSTIC FEATURES OF TERATOMAS WITH MALIGNANT TRANSFORMATION: A CLINICOPATHOLOGICAL STUDY OF 21 CASES. <i>Journal of Urology</i> , 1998, 159, 859-863.	0.2	153
362	Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. <i>Urology</i> , 1996, 48, 741-746.	0.5	8
363	Tumour suppression by the human von Hippel-Lindau gene product. <i>Nature Medicine</i> , 1995, 1, 822-826.	15.2	636
364	Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. <i>ELife</i> , 0, 11, .	2.8	15